$TXMD
TherapeuticsMD, Inc.

2022 Q4 Form 10-Q Financial Statement

#000156459022037666 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $1.152M $20.92M $25.41M
YoY Change -93.83% -17.67% 31.35%
Cost Of Revenue -$11.99M $3.788M $5.282M
YoY Change -353.13% -28.28% 61.09%
Gross Profit $13.14M $17.13M $20.12M
YoY Change -5.72% -14.88% 25.28%
Gross Profit Margin 1140.89% 81.89% 79.21%
Selling, General & Admin $2.458M $36.76M $58.44M
YoY Change -94.87% -37.09% 49.81%
% of Gross Profit 18.7% 214.63% 290.4%
Research & Development $1.112M $1.605M
YoY Change -30.72% -20.82%
% of Gross Profit 6.49% 7.98%
Depreciation & Amortization -$1.988M $200.0K $200.0K
YoY Change -298.4% 0.0% 0.0%
% of Gross Profit -15.13% 1.17% 0.99%
Operating Expenses -$63.34M $37.88M $60.05M
YoY Change -228.39% -36.92% 46.32%
Operating Profit $76.48M -$20.75M -$39.92M
YoY Change -316.09% -48.03% 59.85%
Interest Expense $4.833M $7.518M
YoY Change -35.71% -2.11%
% of Operating Profit
Other Income/Expense, Net -$100.5M -$8.478M $19.00K
YoY Change -1256587.5% -44721.05% -100.25%
Pretax Income -$33.51M -$29.23M -$47.42M
YoY Change -21.99% -38.37% 45.41%
Income Tax -$290.0K -$300.0K $0.00
% Of Pretax Income
Net Earnings $77.70M -$28.97M -$47.42M
YoY Change -280.87% -38.92% 45.41%
Net Earnings / Revenue 6744.97% -138.48% -186.65%
Basic Earnings Per Share -$3.13 -$5.62
Diluted Earnings Per Share $8.19 -$3.13 -$5.616M
COMMON SHARES
Basic Shares Outstanding 9.467M 9.425M 422.2M
Diluted Shares Outstanding 9.261M 8.444M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $38.07M $27.08M $104.8M
YoY Change -41.55% -74.17% 31.71%
Cash & Equivalents $64.91M $38.33M $104.8M
Short-Term Investments
Other Short-Term Assets $17.28M $21.54M $10.37M
YoY Change 63.86% 107.63% 17.89%
Inventory $6.701M $7.362M
Prepaid Expenses
Receivables $32.16M $37.40M
Other Receivables $0.00 $0.00
Total Short-Term Assets $55.35M $87.48M $160.0M
YoY Change -53.67% -45.32% 30.7%
LONG-TERM ASSETS
Property, Plant & Equipment $78.00K $551.0K $1.388M
YoY Change -93.49% -60.3% -88.34%
Goodwill
YoY Change
Intangibles $6.943M $37.88M $39.62M
YoY Change -82.78% -4.39%
Long-Term Investments
YoY Change
Other Assets $253.0K $253.0K $253.0K
YoY Change 0.0% 0.0% -36.75%
Total Long-Term Assets $35.11M $46.43M $49.65M
YoY Change -29.79% -6.49% -9.56%
TOTAL ASSETS
Total Short-Term Assets $55.35M $87.48M $160.0M
Total Long-Term Assets $35.11M $46.43M $49.65M
Total Assets $90.46M $133.9M $209.6M
YoY Change -46.62% -36.12% 18.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.162M $13.38M $19.59M
YoY Change -89.36% -31.69% 21.69%
Accrued Expenses $17.24M $38.76M $47.05M
YoY Change -57.63% -17.62% 127.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $93.60M $15.00M
YoY Change -100.0% 524.01%
Total Short-Term Liabilities $46.84M $174.1M $86.27M
YoY Change -81.48% 101.78% 82.38%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $171.7M
YoY Change -100.0% -27.57%
Other Long-Term Liabilities $1.107M $554.0K $8.984M
YoY Change -48.25% -93.83% 0.94%
Total Long-Term Liabilities $1.107M $554.0K $171.7M
YoY Change -48.25% -99.68% -30.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $46.84M $174.1M $86.27M
Total Long-Term Liabilities $1.107M $554.0K $171.7M
Total Liabilities $55.32M $182.2M $267.0M
YoY Change -78.98% -31.77% -8.97%
SHAREHOLDERS EQUITY
Retained Earnings -$939.4M -$1.017B
YoY Change -10.65%
Common Stock $974.5M $968.8M
YoY Change 1.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $35.14M -$48.27M -$57.36M
YoY Change
Total Liabilities & Shareholders Equity $90.46M $133.9M $209.6M
YoY Change -46.62% -36.12% 18.23%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income $77.70M -$28.97M -$47.42M
YoY Change -280.87% -38.92% 45.41%
Depreciation, Depletion And Amortization -$1.988M $200.0K $200.0K
YoY Change -298.4% 0.0% 0.0%
Cash From Operating Activities $59.77M -$18.92M -$38.22M
YoY Change -251.1% -50.5% 12.26%
INVESTING ACTIVITIES
Capital Expenditures $37.00K -$31.00K -$182.0K
YoY Change -102.44% -82.97% -30.0%
Acquisitions
YoY Change
Other Investing Activities $81.20M $0.00
YoY Change
Cash From Investing Activities $81.16M -$31.00K -$182.0K
YoY Change -5460.83% -82.97% -30.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -129.9M 19.73M 31.82M
YoY Change -9704.43% -38.01% 31722.0%
NET CHANGE
Cash From Operating Activities 59.77M -18.92M -38.22M
Cash From Investing Activities 81.16M -31.00K -182.0K
Cash From Financing Activities -129.9M 19.73M 31.82M
Net Change In Cash 10.99M 777.0K -6.583M
YoY Change -127.66% -111.8% -80.76%
FREE CASH FLOW
Cash From Operating Activities $59.77M -$18.92M -$38.22M
Capital Expenditures $37.00K -$31.00K -$182.0K
Free Cash Flow $59.74M -$18.89M -$38.04M
YoY Change -257.02% -50.35% 12.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q4 us-gaap Cash
Cash
65122000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32157000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
36176000
CY2022Q3 us-gaap Inventory Net
InventoryNet
6701000
CY2021Q4 us-gaap Inventory Net
InventoryNet
7622000
CY2021Q4 us-gaap Assets
Assets
169472000
CY2022Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
93602000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
188269000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20917000
CY2021Q3 us-gaap Gross Profit
GrossProfit
20124000
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
19129000
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
30005000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17635000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28435000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1112000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1605000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
37876000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
60045000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20747000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-39921000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9467104
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25406000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
68811000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3788000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5282000
CY2022Q3 us-gaap Gross Profit
GrossProfit
17129000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
87478000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
551000
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
37876000
CY2022Q3 us-gaap Assets
Assets
133907000
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.02
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.02
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.02
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.02
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y9M18D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y4M24D
CY2022Q3 us-gaap Cash
Cash
27080000
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
11250000
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1621000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1334000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10290000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10548000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
119468000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1199000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
40318000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7749000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8234000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
253000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
253000
CY2022Q3 txmd Lender Warrants Derivative Liability
LenderWarrantsDerivativeLiability
2058000
CY2022Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1751000
CY2022Q3 txmd Mandatory Redeemable Preferred Stock
MandatoryRedeemablePreferredStock
19709000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
13383000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
20318000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
43568000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
44304000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
174071000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
252891000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-112000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
9000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
9000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
968785000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
957730000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7553000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8063000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
554000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2139000
CY2022Q3 us-gaap Liabilities
Liabilities
182178000
CY2021Q4 us-gaap Liabilities
Liabilities
263093000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
22000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
22000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1017065000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1051360000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-48271000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-93621000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
133907000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
169472000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
68273000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13388000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14101000
us-gaap Gross Profit
GrossProfit
55423000
us-gaap Gross Profit
GrossProfit
54172000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
61703000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
86193000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
55445000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
66691000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4092000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5666000
us-gaap Operating Expenses
OperatingExpenses
121240000
us-gaap Operating Expenses
OperatingExpenses
158550000
us-gaap Operating Income Loss
OperatingIncomeLoss
-65817000
us-gaap Operating Income Loss
OperatingIncomeLoss
-104378000
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
143384000
CY2022Q3 txmd Accretion Expense Of Mandatory Redeemable Preferred Stock
AccretionExpenseOfMandatoryRedeemablePreferredStock
3457000
txmd Accretion Expense Of Mandatory Redeemable Preferred Stock
AccretionExpenseOfMandatoryRedeemablePreferredStock
3457000
CY2022Q3 txmd Fair Value Gain Loss On Lender Warrants Derivative Liability
FairValueGainLossOnLenderWarrantsDerivativeLiability
-76000
txmd Fair Value Gain Loss On Lender Warrants Derivative Liability
FairValueGainLossOnLenderWarrantsDerivativeLiability
-76000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-8380000
CY2022Q3 us-gaap Interest Expense
InterestExpense
4833000
CY2021Q3 us-gaap Interest Expense
InterestExpense
7518000
us-gaap Interest Expense
InterestExpense
30941000
us-gaap Interest Expense
InterestExpense
25341000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-16.68
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9261000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8444000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8877000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
19000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-128000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
264000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8478000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7499000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
100402000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-25077000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29225000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47420000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
34585000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-129455000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-260000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
290000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-28965000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-47420000
us-gaap Net Income Loss
NetIncomeLoss
34295000
us-gaap Net Income Loss
NetIncomeLoss
-129455000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.13
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.62
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7762000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.13
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-16.68
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9261000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8444000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9205000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7762000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-28965000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-47420000
us-gaap Net Income Loss
NetIncomeLoss
34295000
us-gaap Net Income Loss
NetIncomeLoss
-129455000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28965000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47420000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
34295000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-129455000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-93621000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2062000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-49021000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-140580000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
14000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2219000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
112281000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-26066000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2454000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4306000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-28965000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-48271000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-124001000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
150899000
CY2021Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
50000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2957000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-39383000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-9478000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
163000
CY2021Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
249000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
134000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2510000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-42652000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-49074000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
31819000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7312000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-47420000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-57360000
us-gaap Net Income Loss
NetIncomeLoss
34295000
us-gaap Net Income Loss
NetIncomeLoss
-129455000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3181000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3091000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
542000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
540000
txmd Inventory Charge
InventoryCharge
73000
txmd Inventory Charge
InventoryCharge
1082000
us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
20053000
us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
4158000
us-gaap Share Based Compensation
ShareBasedCompensation
8587000
us-gaap Share Based Compensation
ShareBasedCompensation
12779000
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
143384000
txmd Accretion Expense Of Mandatory Redeemable Preferred Stock
AccretionExpenseOfMandatoryRedeemablePreferredStock
3457000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-8380000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
50000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
726000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3044000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5560000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-848000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
451000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-180000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2831000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6186000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1476000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3705000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
13504000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-675000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
758000
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-98145000
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
26320000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-63850000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-103135000
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
142634000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
297000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
675000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
34000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
142316000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-709000
us-gaap Proceeds From Issuance Of Redeemable Preferred Stock
ProceedsFromIssuanceOfRedeemablePreferredStock
16252000
us-gaap Proceeds From Derivative Instrument Financing Activities
ProceedsFromDerivativeInstrumentFinancingActivities
1751000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2454000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
182881000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
302000
txmd Proceeds From Sale Of Common Stock Related To Employee Stock Purchase Plan
ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan
14000
txmd Proceeds From Sale Of Common Stock Related To Employee Stock Purchase Plan
ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan
134000
us-gaap Repayments Of Debt
RepaymentsOfDebt
125000000
us-gaap Repayments Of Debt
RepaymentsOfDebt
50000000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
729000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
5118000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-105258000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
128199000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-26792000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
24355000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65122000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80486000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38330000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104841000
us-gaap Interest Paid Net
InterestPaidNet
8371000
us-gaap Interest Paid Net
InterestPaidNet
19675000
txmd Non Cash Payment Of Interest And Increase In Debt
NonCashPaymentOfInterestAndIncreaseInDebt
2452000
txmd Non Cash Payment Of Financing Fees And Increase In Debt
NonCashPaymentOfFinancingFeesAndIncreaseInDebt
16980000
txmd Issue Of Warrants Lenders Related To Debt Financing Fees
IssueOfWarrantsLendersRelatedToDebtFinancingFees
1983000
us-gaap Operating Income Loss
OperatingIncomeLoss
-65800000
us-gaap Interest Expense
InterestExpense
30900000
txmd Current Liabilities Over Current Assets During Period
CurrentLiabilitiesOverCurrentAssetsDuringPeriod
86600000
txmd Liabilities Over Assets During Period
LiabilitiesOverAssetsDuringPeriod
48300000
CY2022Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
outstanding shares of our Common Stock were split at a ratio of 50-for-1
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000.0
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
12000000.0
us-gaap Use Of Estimates
UseOfEstimates
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">C.</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Estimates and assumptions</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity to U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We evaluate our estimated assumptions based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.</p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="Background-color:#FFFFFF;margin-bottom:0pt;text-align:justify;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">E.</span></p></td> <td valign="top"> <p style="Background-color:#FFFFFF;margin-bottom:0pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Reclassification of prior year presentation</p></td></tr></table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="Background-color:#FFFFFF;text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported consolidated balance sheets and consolidated statements of cash flows. An adjustment has been made to the consolidated statements of operations for the three and nine months ended September 30, 2021 to reclassify vitaCare service revenue.</p>
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1334000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
542000
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
255000
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1621000
CY2021Q4 txmd Accrued Sales Returns Reserve And Coupons Current
AccruedSalesReturnsReserveAndCouponsCurrent
2422000
CY2022Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
3475000
CY2021Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
2850000
CY2022Q3 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1946000
CY2021Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
3042000
CY2022Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
218000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1642000
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4537000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2938000
CY2022Q3 us-gaap Inventory Net
InventoryNet
6701000
CY2021Q4 us-gaap Inventory Net
InventoryNet
7622000
CY2022Q3 txmd Inventory Charge
InventoryCharge
0
txmd Inventory Charge
InventoryCharge
100000
CY2021Q3 txmd Inventory Charge
InventoryCharge
600000
txmd Inventory Charge
InventoryCharge
1100000
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
2370000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2731000
CY2022Q3 txmd Paragraph Four Legal Proceeding Costs
ParagraphFourLegalProceedingCosts
2334000
CY2021Q4 txmd Paragraph Four Legal Proceeding Costs
ParagraphFourLegalProceedingCosts
2304000
CY2022Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
5586000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
5513000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10290000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10548000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3717000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3547000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2996000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2518000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
551000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1199000
CY2022Q3 us-gaap Depreciation
Depreciation
200000
CY2021Q3 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
500000
us-gaap Depreciation
Depreciation
600000
CY2022Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
48125000
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
10570000
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
37555000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
47854000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
39986000
CY2022Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
48446000
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
10570000
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
37876000
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
48186000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
7868000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
40318000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8460000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13764000
CY2022Q3 txmd Accrued Rebates Current
AccruedRebatesCurrent
16854000
CY2021Q4 txmd Accrued Rebates Current
AccruedRebatesCurrent
11010000
CY2022Q3 txmd Accrued Sales Returns Reserve And Coupons Current
AccruedSalesReturnsReserveAndCouponsCurrent
3434000
CY2022Q3 txmd Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1826000
CY2021Q4 txmd Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1995000
CY2022Q3 txmd Accrued Wholesale Distributor Fees
AccruedWholesaleDistributorFees
4520000
CY2021Q4 txmd Accrued Wholesale Distributor Fees
AccruedWholesaleDistributorFees
3614000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
739000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2571000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1383000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1361000
CY2022Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
290000
CY2022Q3 txmd Other Accrued Expenses And Current Liabilities
OtherAccruedExpensesAndCurrentLiabilities
2587000
CY2021Q4 txmd Other Accrued Expenses And Current Liabilities
OtherAccruedExpensesAndCurrentLiabilities
4717000
CY2022Q3 txmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
43568000
CY2021Q4 txmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
44304000
CY2022Q3 us-gaap Advertising Expense
AdvertisingExpense
4800000
CY2021Q3 us-gaap Advertising Expense
AdvertisingExpense
14600000
us-gaap Advertising Expense
AdvertisingExpense
12600000
us-gaap Advertising Expense
AdvertisingExpense
34400000
CY2022Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
830000
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
11731000
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
93602000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
188269000
CY2022Q3 txmd Warrants Derivative Liability
WarrantsDerivativeLiability
2100000
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
100000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
100000
CY2022Q3 us-gaap Paid In Kind Interest
PaidInKindInterest
2500000
us-gaap Paid In Kind Interest
PaidInKindInterest
2500000
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
2251000
CY2021Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
5391000
us-gaap Interest Expense Debt
InterestExpenseDebt
10888000
us-gaap Interest Expense Debt
InterestExpenseDebt
17175000
CY2021Q3 txmd Debt Interest Prepayment Fee
DebtInterestPrepaymentFee
650000
txmd Debt Interest Prepayment Fee
DebtInterestPrepaymentFee
4008000
CY2022Q3 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
2582000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12800000
CY2021Q3 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
1477000
us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
20053000
us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
4158000
CY2022Q3 us-gaap Interest Expense
InterestExpense
4833000
CY2021Q3 us-gaap Interest Expense
InterestExpense
7518000
us-gaap Interest Expense
InterestExpense
30941000
us-gaap Interest Expense
InterestExpense
25341000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
353000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
225.98
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
336000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
230.93
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1885.39
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
155000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
238.45
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
197000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
216.65
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
192000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
219.65
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4300000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7300000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8600000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
6100000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2022Q3 txmd Share Based Payment Arrangement Nonvested Award Option Cost Not Yet Recognized Remainder Of Fiscal Year
ShareBasedPaymentArrangementNonvestedAwardOptionCostNotYetRecognizedRemainderOfFiscalYear
1098000
CY2022Q3 txmd Share Based Payment Arrangement Nonvested Award Option Cost Not Yet Recognized Year One
ShareBasedPaymentArrangementNonvestedAwardOptionCostNotYetRecognizedYearOne
3255000
CY2022Q3 txmd Share Based Payment Arrangement Nonvested Award Option Cost Not Yet Recognized Year Two
ShareBasedPaymentArrangementNonvestedAwardOptionCostNotYetRecognizedYearTwo
1556000
CY2022Q3 txmd Share Based Payment Arrangement Nonvested Award Option Cost Not Yet Recognized Year Three
ShareBasedPaymentArrangementNonvestedAwardOptionCostNotYetRecognizedYearThree
157000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6066000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20917000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25406000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
68811000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
68273000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-300000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
300000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
50-for-1 reverse stock split
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-28965000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-47420000
us-gaap Net Income Loss
NetIncomeLoss
34295000
us-gaap Net Income Loss
NetIncomeLoss
-129455000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9261000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8444000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8877000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7762000
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2021Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
328000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9261000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8444000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9205000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7762000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.13
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-16.68
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.13
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-16.68
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1009000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
989000
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
989000

Files In Submission

Name View Source Status
0001564590-22-037666-index-headers.html Edgar Link pending
0001564590-22-037666-index.html Edgar Link pending
0001564590-22-037666.txt Edgar Link pending
0001564590-22-037666-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gkoneh2dslj1000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
txmd-10q_20220930.htm Edgar Link pending
txmd-20220930.xsd Edgar Link pending
txmd-ex101_163.htm Edgar Link pending
txmd-ex102_164.htm Edgar Link pending
txmd-ex103_165.htm Edgar Link pending
txmd-ex104_162.htm Edgar Link pending
txmd-20220930_def.xml Edgar Link unprocessable
txmd-20220930_lab.xml Edgar Link unprocessable
txmd-20220930_pre.xml Edgar Link unprocessable
txmd-10q_20220930_htm.xml Edgar Link completed
txmd-ex311_9.htm Edgar Link pending
txmd-ex312_48.htm Edgar Link pending
txmd-ex313_8.htm Edgar Link pending
txmd-ex321_7.htm Edgar Link pending
txmd-ex322_49.htm Edgar Link pending
txmd-ex323_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
txmd-20220930_cal.xml Edgar Link unprocessable